True North Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

True North Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,800	Closed	-$503K	–	199
2023 Q2	$503K	Sell	5,800 -2,900	-33%	-$273K	0.14%	123
2023 Q1	$846K	Hold	8,700	–	–	0.25%	89
2022 Q4	$900K	Hold	8,700	–	–	0.31%	79
2022 Q3	$737K	Hold	8,700	–	–	0.24%	86
2022 Q2	$720K	Hold	8,700	–	–	0.22%	96
2022 Q1	$670K	Hold	8,700	–	–	0.18%	107
2021 Q4	$768K	Hold	8,700	–	–	0.13%	125
2021 Q3	$672K	Hold	8,700	–	–	0.13%	131
2021 Q2	$725K	Buy	8,700 +3,200	+58%	+$254K	0.15%	118
2021 Q1	$415K	Hold	5,500	–	–	0.1%	146
2020 Q4	$482K	Buy	5,500 +2,619	+91%	+$208K	0.12%	125
2020 Q3	$219K	Buy	+2,881	New	+$291K	0.06%	165

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

True North Advisors's BMRN Position: Q3 2023 in Review

True North Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 5,800 shares — an estimated $503K sold.

True North Advisors first reported a position in BMRN in Q3 2020 and held it in 12 quarters. The position peaked at $900K in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

True North Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
True North Advisors sold 5,800 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $503K.
True North Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 12 quarters.
True North Advisors's BioMarin Pharmaceuticals position peaked at $900K in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on True North Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.